Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA- identical sibling bone marrow transplantation: Results of a randomized trial

Franco Locatelli, Marco Zecca, Roberto Rondelli, Federico Bonetti, Giorgio Dini, Arcangelo Prete, Chiara Messina, Cornelio Uderzo, Mimmo Ripaldi, Fulvio Porta, Giovanna Giorgiani, Eugenia Giraldi, Andrea Pession

Research output: Contribution to journalArticlepeer-review

Abstract

Leukemia relapse is a major cause of treatment failure for patients with acute leukemia given allogeneic bone marrow transplantation (BMT). This study evaluated whether a reduction of the dosage of cyclosporine-A (Cs-A) used for graft versus host disease (GVHD) prophylaxis could reduce relapse rate (RR) in children with acute leukemia given BMT. Fifty-nine children who had transplantation from HLA-identical siblings were randomized to receive Cs-A intravenously at a dosage of 1 mg/kg/d (Cs-A1) or of 3 mg/kg/d (Cs-A3) until patients were able to tolerate oral intake. Subsequently, both groups received Cs-A orally at a dosage of 6 mg/kg/d, with discontinuation 5 months after BMT. The probability of developing grade II-IV acute GVHD was 57% for the Cs-A1 group versus 38% for the Cs-A3 group (P = .06); the probability of developing chronic GVHD was 30% for the Cs-A1 group and 26% for the Cs-A3 group (P = NS). Three patients died of grade IV acute GVHD: 2 were in the Cs- A1 and the third in the Cs-A3 group. The RR was 15% for the Cs-A1 group and 41% for the Cs-A3 group (P = .034); 1-year transplant-related mortality estimates were 17% and 7%, respectively (P = NS). With a median observation time of 44 months from BMT, the 5-year event-free survival for children belonging to Cs-A1 and Cs-A3 groups was 70% and 51%, respectively (P = .15). Our data demonstrate that the use of low Cs-A doses is associated with a statistically significant reduction of leukemia relapse, probably due to an increased graft versus leukemia effect. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)1572-1579
Number of pages8
JournalBlood
Volume95
Issue number5
Publication statusPublished - Mar 1 2000

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA- identical sibling bone marrow transplantation: Results of a randomized trial'. Together they form a unique fingerprint.

Cite this